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Many countries are facing social and economic problems due to increased elderly demographics.
With these demands, it is now critical to understand the fundamental regulatory mechanism for
aging and longevity in mammals. Our studies on the mammalian NAD-dependent deacetylase SIRT1
and nicotinamide phosphoribosyltransferase (NAMPT)-mediated systemic NAD biosynthesis led us
to propose a comprehensive model for the systemic regulatory network connecting metabolism
and aging, termed the ‘‘NAD World’’. In this article, I will discuss the importance of SIRT1 and
NAMPT-mediated NAD biosynthesis in the NAD World and the system dynamics of this hierarchical
network for the connection between metabolism and aging.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Studies using experimental model organisms such as yeast,A number of European countries such as Germany, Italy, Spain,
Sweden, Greece, and Austria, and Japan are on the verge of serious
social and economic problems due to historically unprecedented
increases in their elderly demographics [1,2]. This population shift
has been implicated to cause labor shortage and signiﬁcantly sup-
press economic growth in these countries. It will also put a pres-
sure on governmental budgets on health and long-term care.
Indeed, the Organisation for Economic Co-operation and Develop-
ment (OECD) has projected that average health and long-term care
spending across OECD countries would be almost doubled from
7% of GDP in 2005 to 13% in 2050 if no policy action is taken
[3]. Interestingly, in this OECD’s projection, it is assumed that lon-
gevity gains could be translated into additional years of good
health, deﬁned as ‘‘healthy aging’’. However, how we can practi-
cally achieve this goal still remains unclear. Given that aging per
se is one of the serious risk factors for many chronic, costly dis-
eases such as cancer, Alzheimer’s disease, and type 2 diabetes, it
is critical to better understand the fundamental mechanisms of
aging and longevity and develop effective, affordable, anti-aging
interventions to prevent those expensive diseases of aging.chemical Societies. Published by E
ashington University School
ue, St. Louis, MO 63110, USA.worms, ﬂies, and mice have already identiﬁed a number of evolu-
tionarily conserved regulators and signaling pathways for the con-
trol of aging and longevity, including insulin/insulin-like growth
factor-I (IGF-I) signaling [4], mammalian target of rapamycin
(mTOR) signaling [5,6], AMP-activated protein kinase (AMPK) sig-
naling [7,8], and NAD-dependent sirtuins [9,10]. Because all these
regulators and signaling pathways are known to play important
roles in metabolic regulation, an intimate connection between
metabolic and aging regulatory mechanisms has been implicated,
stimulating researchers to dissect temporal and spatial dynamics
of complex regulatory networks in each model organism. Whereas
interplays between known regulators and signaling pathways are
being investigated extensively [9], drawing a blueprint of such
aging regulatory networks still remains a big challenge. To further
dissect systemic regulatory networks of aging, there are several
fundamental questions that need to be addressed: (1) which or-
gans and tissues have dominant roles in the systemic regulation
of mammalian aging and longevity?; (2) how do these ‘‘control
centers’’ communicate with other organs and tissues to manage
the process of aging and eventually longevity in mammals?; (3)
what are the molecular regulators and signaling pathways that
coordinate such a regulatory network at a systemic level?
In this article, I will attempt to provide insight into these
fundamental questions, focusing on the roles of the mammalian
NAD-dependent deacetylase SIRT1 and nicotinamide phosphoribo-
syltransferase (NAMPT)-mediated systemic NAD biosynthesis inlsevier B.V. All rights reserved.
1658 S. Imai / FEBS Letters 585 (2011) 1657–1662the regulation of metabolism and aging. SIRT1 functions as a key
mediator that orchestrates metabolic responses to changes in
nutritional availability in multiple tissues, whereas NAMPT-medi-
ated NAD biosynthesis functions as a pace maker that regulates cir-
cadian oscillatory NAD production and ﬁne-tunes SIRT1 activity at
a systemic level [9–13]. Through such an intricate functional inter-
play, these two components comprise a systemic regulatory net-
work that maintains the robustness of our physiological system
in response to a variety of nutritional and environmental stimuli,
which we have termed the ‘‘NAD World’’ [13–15]. I will introduce
the concept of the NAD World and discuss its implication for the
connection between metabolism and aging.Fig. 1. The role of SIRT1 in mediating adaptive responses to limited energy intake.
SIRT1 mediates adaptive responses to acute and chronic energy limitation, such as
fasting and diet restriction, and maintains the robustness of our physiological
system by increasing blood glucose levels, utilizing fatty acid as an alternative
energy source, and triggering neurobehavioral regulatory pathways in multiple
tissues indicated.2. The mammalian NAD-dependent protein deacetylase SIRT1
SIR2 (silent information regulator 2) family proteins, now called
‘‘sirtuins’’, are evolutionarily conserved from bacteria to humans
and characterized by the signature structural motif called the core
domain that is necessary for their NAD-dependent deacetylase or
ADP-ribosyltransferase activities [10]. In mammals, there are seven
sirtuins, SIRT1 through SIRT7, with highly divergent cellular local-
izations and functions [10]. Numerous studies in the past 10 years
have ﬁrmly established that mammalian sirtuins, particularly
SIRT1, regulate metabolic responses to changes in nutritional avail-
ability in multiple tissues [9,10,16–18].
Accumulating bodies of evidence have suggested that SIRT1
plays an important role in retarding age-associated pathophysio-
logical changes and preventing from diseases of aging, such as type
2 diabetes, Alzheimer’s disease, and cancer. Whole-body SIRT1-
overexpressing transgenic mice show signiﬁcant protection from
the adverse effects of high-fat diet or aging on glucose metabolism
[9,10]. SIRT1-activating compounds are also able to improve glu-
cose homeostasis and insulin sensitivity in diet-induced and genet-
ic type 2 diabetes animal models [9,10]. It has recently been
demonstrated that SIRT1 prevents two critical pathological aspects
of Alzheimer’s disease: Ab amyloid deposition and tauopathy.
SIRT1 decreases the production of Ab amyloid by deacetylating
the retinoic acid receptor b and thereby up-regulating ADAM10,
a major component of a-secretase [19]. SIRT1 also promotes degra-
dation of phosphorylated tau by deacetylating it and prevents tau-
mediated neurodegeneration [20]. Furthermore, SIRT1 regulates
memory and synaptic plasticity, providing insight into potential
intervention against age-associated cognitive disorders [21,22]. It
has also been reported that SIRT1 transgenic mice show a lower
incidence of spontaneous carcinomas and sarcomas and a reduced
susceptibility to high-fat diet/carcinogen-induced liver tumors,
compared to wild-type control mice [23]. These ﬁndings provide
strong support for the importance of SIRT1 in the prevention of
major age-associated diseases.
How can SIRT1 connect metabolic regulation to aging regula-
tion? A key to understanding this important connection is the fact
that SIRT1 is required to regulate adaptive responses to acute and
chronic energy limitations, such as fasting and dietary restriction
(Fig. 1). For example, during fasting, peripheral tissues try to
preserve blood glucose levels to maintain the functions of glu-
cose-dependent tissues, particularly the brain. In the liver, SIRT1
represses glycolytic genes and up-regulates gluconeogenic genes
by deacetylating PGC-1a, FOXO1, and STAT3, resulting in increased
glucose production [24–27]. In white adipose tissue (WAT), SIRT1
mediates fatty acid mobilization by repressing PPARc [28]. In skel-
etal muscle, the coordinated activation of AMPK and SIRT1 induces
deacetylation of PGC-1a and FOXO1, switching the main energy
source from glucose to fatty acids and enhancing their b-oxidation
in mitochondria [29,30]. When energy limitation persists, the body
triggers its adaptive mechanisms that enable individual animals tosurvive through nutritionally scarce conditions. In the hypothala-
mus, diet restriction signiﬁcantly increases SIRT1 protein levels
and thereby induces neural activation in the dorsomedial and lat-
eral hypothalamic nuclei (DMH and LH, respectively), resulting in
the increase in physical activity and counteracting the decrease
in body temperature through the enhancement of the orexin type
2 receptor expression [31]. In pancreatic b cells, diet restriction
enhances their postprandial insulin secretion [32, and our unpub-
lished ﬁndings], which is phenocopied in pancreatic b cell-speciﬁc
SIRT1-overexpressing (BESTO) mice [33]. In WAT, adiponectin
production, which is regulated by SIRT1, increases in response to
diet restriction, enhancing peripheral insulin sensitivity [34,35].
All these SIRT1-mediated adaptive responses to energy limitation
are critical to keep our physiological system as robust as possible,
by increasing blood glucose levels, utilizing fatty acid as an alterna-
tive energy source, and triggering neurobehavioral regulatory
pathways, even under such nutritionally challenging conditions.
During evolution, this exact function of SIRT1 and its orthologs
might have become beneﬁcial for organisms to keep their physio-
logical system robust over a long period of time, culminating in the
mechanism that affects the process of aging and eventually deter-
mines longevity within the limit of each organism’s ecosystem.
Based on this speculation, the organs and tissues in which SIRT1
function can be easily compromised by nutritional and environ-
mental perturbations would be the frailty points for both meta-
bolic and aging regulations in our physiological system. How can
we identify such tissues and organs? Studies on mammalian NAD
biosynthesis have provided an important clue to identify these po-
tential frailty points, which will be discussed further below.
3. NAMPT-mediated systemic NAD biosynthesis
Because sirtuins absolutely require NAD for their enzymatic
activities, how NAD is synthesized and supplied to sirtuins is
important to understand the system dynamics of the NAD World.
Interestingly, the functional connection between NAD biosynthesis
Fig. 2. A circadian oscillatory feedback loop regulated by NAMPT, SIRT1, and
CLOCK/BMAL1 and a possible functional interplay between adipose tissue and two
frailty tissues in the NAD World, pancreatic b cells and neurons. NAMPT and NAD
levels display circadian oscillations that are regulated by CLOCK/BMAL1 in
peripheral tissues, such as the liver and WAT. This NAD oscillation periodically
activates SIRT1, which represses CLOCK/BMAL1-mediated transcription of clock
target genes, including Nampt itself, completing an interlocked transcriptional-
enzymatic feedback loop involving NAMPT-NAD and SIRT1-CLOCK/BMAL1. In
pancreatic b cells and central neurons, intracellular NAMPT (iNAMPT) levels are
so low [45] that they may not be able to drive the NAMPT–NAD–SIRT1-dependent
circadian feedback loop. However, their NAD oscillation might be generated by
incorporating NMN that is likely synthesized from nicotinamide (Nic) by extracel-
lular NAMPT (eNAMPT) that could be periodically secreted from adipose tissue.
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synthetic enzymes (Nampt and Nmnat, described below) and a sir-
tuin have been identiﬁed in the T4-like, broad host range
vibriophage KVP40, implicating that this connection is fundamen-
tal [37]. Indeed, these particular enzymes are highly conserved in
mammals.
NAD is synthesized from three major precursors—tryptophan,
nicotinic acid, and nicotinamide [38,39]. Lower eukaryotes and
invertebrates, such as yeast, worms, and ﬂies, use nicotinic acid,
a form of vitamin B3, as a major NAD precursor, whereas mammals
predominantly use nicotinamide, another form of vitamin B3, for
NAD biosynthesis. In mammals, NAMPT initiates the major NAD
biosynthesis pathway by converting nicotinamide and 50-phospho-
ribosyl-1-pyrophosphate (50-PRPP) to nicotinamide mononucleo-
tide (NMN), which is the rate-limiting step in this NAD
biosynthesis [11,12]. The second enzyme, nicotinamide/nicotinic
acid mononucleotide adenylyltransferase (NMNAT), completes
NAD biosynthesis by transferring adenine from ATP to NMN. There
are three distinct isoforms for NMNAT, NMNAT1-3, which are
localized in nucleus, cytoplasm, and mitochondria, respectively,
suggesting that NAD biosynthesis mediated by NAMPT and
NMNAT might be compartmentalized in each subcellular compart-
ment [40,41].
The enzymological features and the crystal structures of NAMPT
have been studied extensively [36,42–44]. NAMPT belongs to a di-
meric class of type II phosphoribosyltransferases. Interestingly, in
mammals, NAMPT has both intra- and extracellular forms, deﬁned
as iNAMPT and eNAMPT, respectively [45]. eNAMPT (a.k.a. PBEF/
visfatin) is actively secreted through an unidentiﬁed, non-classical
secretory pathway from mouse and human matured adipocytes
[45]. This secretion process appears to be regulated by protein
modiﬁcation in response to nutritional changes (our unpublished
observation). Furthermore, eNAMPT secreted from matured adipo-
cytes is approximately twice as active as iNAMPT [45], implying
that the secretion and the activity of eNAMPT might be tightly reg-
ulated in adipocytes. It has been reported that hepatocytes, macro-
phages, and leukocytes also produce eNAMPT [46–48]. One recent
study has demonstrated an interesting correlation between serum
eNAMPT levels and circulating leukocyte counts, speculating that
leukocytes might be a major source of circulating eNAMPT [47]. Gi-
ven that NAMPT-mediated NAD biosynthesis is critical for neutro-
philic granulocyte differentiation in humans [49], it is equally
possible that increased eNAMPT levels promote leukocyte differen-
tiation, resulting in increases in circulating leukocyte counts. Addi-
tionally, it should be noted that brown adipose tissue and
adipocytes also express very high levels of NAMPT mRNA and pro-
tein and are capable of secreting eNAMPT in response to nutri-
tional changes [45, and our unpublished ﬁndings]. Therefore,
which cell type is indeed the major source of circulating eNAMPT
and which cell type mainly contributes to the regulation of circu-
lating eNAMPT levels remain unclear at this moment. Whatever
its major source is, signiﬁcant amounts of eNAMPT exist in mouse
and human blood circulation, and circulating eNAMPT mainly
takes the enzymatically active dimer form in normal human serum
[45,50]. Based on these ﬁndings, it has been proposed that eNAMPT
contributes to extracellular biosynthesis of NMN that is distributed
to all tissues and organs to promote NAD biosynthesis at a systemic
level [12,15]. Indeed, major metabolic tissues can rapidly incorpo-
rate NMN from blood circulation and utilize it for NAD biosynthe-
sis (our unpublished results).
Recent studies have clearly demonstrated the tight functional
connection between NAMPT-mediated NAD biosynthesis and sir-
tuins, particularly SIRT1, in a number of different cell types, includ-
ing pancreatic b cells, vascular smooth muscle cells, skeletal
myoblasts, cardiac myocytes, granulocytes, and others [11,13]. In
these cell types, the NAMPT–SIRT1 pathway regulates metabolicresponse, cellular differentiation and life span, cell death, and other
important biological events. Among these ﬁndings, the most
important to understand the system dynamics of the NAD World
is the discovery that NAMPT-mediated NAD biosynthesis and
SIRT1 comprise a novel feedback loop in which NAD functions as
a ‘‘metabolic oscillator’’ and regulates the core circadian clock
machinery through SIRT1 and CLOCK/BMAL1, a key clock regula-
tory complex (Fig. 2) [51,52]. In this feedback loop, levels of
NAMPT and NAD display circadian oscillations that are regulated
by CLOCK/BMAL1 in peripheral tissues, such as the liver and
WAT. This NAD oscillation leads to periodic activation of SIRT1,
which represses CLOCK/BMAL1-mediated transcription of clock
target genes [53], including Nampt itself (Fig. 2) [51,52]. Therefore,
NAMPT–NAD and SIRT1-CLOCK/BMAL1 create an interlocked tran-
scriptional-enzymatic feedback loop. Given that the core molecular
clock machinery is one of the most powerful modiﬁers of metabo-
lism [54] and also that the importance of physiological rhythmicity
has been implicated for the regulation of metabolism and aging in
the idea of ‘‘the aging clock’’ [55], this discovery has provided the
ﬁrst evidence for the signiﬁcance of the NAMPT–SIRT1 pathway
in the potential connection between physiological rhythmicity,
metabolism, and aging in the NAD World [13]. Further investiga-
tion is required to examine whether this particular rhythmicity
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the regulation of aging and possibly longevity in mammals.4. Frailty points in the NAD World and the hierarchical view of
mammalian aging
Every system has certain frailty points that play an important
role in determining the robustness of the system. In the concept
of the NAD World, critical frailty points are the tissues and organs
that have very low levels of iNAMPT and, therefore, must rely on
circulating NMN to maintain sufﬁcient NAD biosynthesis to func-
tion. Pancreatic b cells and neurons, both of which have very low
levels of iNAMPT (Fig. 2) [45, our unpublished observation], are
likely the most important frailty tissues whose functional defects
have serious inﬂuences on many other tissues and affect the
robustness of our physiological system. Indeed, a decrease in
NAMPT-mediated systemic NAD biosynthesis causes impaired glu-
cose tolerance in Nampt heterozygous mice, due to signiﬁcant
reduction in glucose-stimulated insulin secretion (GSIS) in pancre-
atic b cells [45]. These defects can be completely ameliorated by
administering NMN, providing strong support to the notion that
pancreatic b cells are one of the signiﬁcant frailty points that are
susceptible to alterations in NAMPT-mediated systemic NAD bio-
synthesis [15,45]. The susceptibility of pancreatic b cells to reduced
NAMPT-mediated systemic NAD biosynthesis has also been dem-
onstrated during aging, causing an age-associated decrease in
SIRT1 activity and GSIS in vivo [56]. Remarkably, NMN administra-
tion can also restore GSIS in aged mice, providing further support
to the frailty of pancreatic b cells in the NAD World [56].
Similarly, the brain (neurons) is likely another critical frailty
point in the NAD World. Given that SIRT1 regulates memory and
synaptic plasticity in the hippocampus [21,22] and neurobehavior-
al adaptation in the hypothalamus [31,57], it is conceivable that
age-associated reduction in systemic NAD biosynthesis could re-
duce SIRT1 activity in these regions and cause neurological prob-
lems, including dementia and neurobehavioral complications
called ‘‘the anorexia of aging’’ [58], in the elderly. If this is the case,
NMN administration might also be able to restore normal NAD bio-
synthesis and ameliorate these neurological problems. Further
investigation is currently underway for the pathophysiological sig-
niﬁcance of systemic NAD biosynthesis and the application of NMN
for the regulation of brain function.
The consideration of critical frailty points in the NADWorld also
provides insight into the hierarchical regulatory system of mam-
malian aging. When systemic NAD biosynthesis declines due to
nutritional and environmental perturbations over time, these
frailty points would be the ﬁrst to respond to this decline and start
having functional defects due to insufﬁcient NAD biosynthesis and
thereby reduced SIRT1 activity. Functional defects in pancreatic b
cells and central neurons cause problems in other peripheral tis-
sues through insulin secretion and central metabolic regulation,
triggering the gradual deterioration of physiological robustness at
a systemic level. This cascade of robustness breakdown triggered
by a decrease in systemic NAD biosynthesis is an important
underlying process during aging. In this regard, the concept of
the NAD World deﬁnes aging as the process in which organismal
robustness gradually shifts and eventually breaks down according
to a functional hierarchy determined by the susceptibility to
systemic NAD biosynthesis. Until recently, aging has been consid-
ered as a plethora of random pathophysiological alterations that
cause global functional decline. However, the paradigm of the
NAD World suggests that there must be a deﬁnable hierarchical
system structure for the control of aging and longevity in
mammals.5. Dissecting the system dynamics of the NAD World
These features of the NAD World, as discussed above, provide
important clues to address the three fundamental questions posed
at the beginning of this article. Regarding which organs and tissues
play dominant roles in the systemic regulation of mammalian
aging, the susceptibility to systemic NAD biosynthesis deﬁnes such
speciﬁc tissues as critical frailty points in the NAD World. Even
though there must be other tissues that are very sensitive to
changes in systemic NAD biosynthesis, it is intriguing that pancre-
atic b cells and central neurons share a similar weakness in this
particular aspect. Both tissues have broad capabilities of regulating
the functions of other tissues through humoral and neural commu-
nications, placing these two frailty points at the top of the aging-
controlling hierarchy as potential ‘‘control centers’’ of aging
(Fig. 3). Consistent with this idea, it has been demonstrated that
a speciﬁc subset of neurons, some of which have a capability of
producing insulin-like peptides, plays a critical role in connecting
metabolic regulation to aging regulation in worms and ﬂies [59].
Thus, it is conceivable that the putative role of both cell types as
‘‘control centers’’ of aging is evolutionarily conserved for the con-
nection between metabolic and aging regulatory mechanisms. In
mammals, SIRT1 in pancreatic b cells and the hypothalamus plays
essential roles in regulating their capabilities of communicating
with other tissues through insulin secretion [33], neuroendocrine
function [60], and possibly autonomic neural networks [31,57].
Therefore, it will be of great importance to test whether enhancing
SIRT1 function in these frailty points might improve the systemic
robustness of the NAD World over time and eventually promote
longevity in mammals.
The idea that pancreatic b cells and central neurons function as
potential ‘‘control centers’’ of aging immediately suggests that
insulin, neuroendocrine hormones, and autonomic nervous system
are likely important communication tools for these tissues to con-
trol the process of aging and eventually longevity in mammals
(Fig. 3). Indeed, studies on Ames and Snell dwarf mice, Ghrhr
(growth hormone releasing hormone receptor) mutant mice, and
the growth hormone receptor/binding protein (GHR/BP)-deﬁcient
mice have ﬁrmly established the importance of the neuroendo-
crine axis, the hypothalamic-pituitary axis in particular, for the
regulation of mammalian aging and longevity [61]. The signiﬁ-
cance of the insulin-secreting capability of pancreatic b cells and
the function of autonomic nervous system for the control of mam-
malian aging and longevity still remains unclear. Nonetheless, it
has been reported that fat-speciﬁc insulin receptor knockout (FIR-
KO) mice show median and maximal lifespan extension [62], sug-
gesting that the interplay between pancreatic b cells and adipose
tissue is important for the regulation of mammalian aging and lon-
gevity. Additionally, transgenic mice overexpressing the uncou-
pling protein 2 in orexin/hypocretin neurons have been reported
to show increased median lifespan [63]. Because orexin signaling
is critical for the regulation of autonomic nervous system [64], it
is likely that the communication between the hypothalamus and
autonomic nervous system contributes to the regulation of aging
and longevity. In this regard, it is of great interest to examine
whether brain-speciﬁc SIRT1-overexpressing (BRASTO) transgenic
mice, which exhibit increased activation of orexin type 2 recep-
tor-positive neurons in the DMH and LH in response to acute and
chronic energy limitation [31], can show signiﬁcant lifespan exten-
sion compared to their control littermates.
Lastly, what molecular regulators and signaling pathways coor-
dinate such a regulatory network at a systemic level? These regu-
lators and signaling pathways must contribute to the stability of
the NAD World. Given that adipose tissue actively secretes eNA-
MPT that has signiﬁcantly higher enzymatic activity compared to
Fig. 3. The aging-controlling hierarchical structure and potential ‘‘control centers’’ of aging in the NADWorld. Pancreatic b cells and central neurons, twomajor frailty points in
the NAD World, determines the hierarchical regulatory cascade for mammalian aging and longevity by communicating with other tissues through insulin, neuroendocrine
hormones, and autonomicnervous system. It is likely that other peripheral tissues also send feedback signals to these ‘‘control centers’’. Adipose tissuemight function as a critical
modulator that coordinates NAD biosynthesis throughout the body and controls the stability of the NADWorld by secreting eNAMPT to blood circulation. See text for details.
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MPT secretion by adipose tissue might be a critical determinant
for the proper coordination of NAD biosynthesis throughout the
body (Fig. 3). Particularly, the regulation of eNAMPT secretion is
important for pancreatic b cells and central neurons, two major
frailty points in the NADWorld, to maintain their normal NAD bio-
synthesis (Fig. 2). Furthermore, if adipose tissue is also capable of
propagating its internal circadian rhythm of iNAMPT expression
to the secretion of eNAMPT and thereby the extracellular biosyn-
thesis of NMN, NAD biosynthesis and SIRT1 activity in those frailty
tissues might be synchronized to display circadian oscillation even
when their iNAMPT levels are not enough to drive their own NAD
oscillation (Fig. 2). This systemic synchronization of NAD biosyn-
thesis might play a critical role in coordinating SIRT1-mediated
metabolic responses in a circadian rhythm-dependent manner,
contributing to the stability of the NAD World against ﬂuctuating
nutritional and environmental perturbations [13]. In this regard,
adipose tissue might function as a critical modulator that deter-
mines the stability of the NADWorld through the secretion of eNA-
MPT (Fig. 3). We are currently analyzing the mechanism of
eNAMPT secretion in adipose tissue and testing the idea regarding
the physiological signiﬁcance of eNAMPT in the NAD World.
6. Perspectives
The importance of the concept of the NAD World is to provide a
foundation to analyze the system dynamics of the regulatory
mechanism for aging and longevity in mammals. Additionally, this
concept raises another important issue of possible trade-offs be-
tween robustness and frailty. Based on the theory of highly opti-
mized tolerance (HOT) architecture [65,66], systems that have
evolved to comprise a greater scale of complexity are optimized
for speciﬁc perturbations but are also inevitably susceptible to
unexpected perturbations. This trade-off between robustness and
frailty is an inherent, unavoidable feature of all complex systems,
including biological systems. Therefore, it is possible that certain
efforts of enhancing the robustness of the system could further
sensitize it to some speciﬁc perturbations [67]. This considerationis becoming more important, particularly when enthusiasm and
demand to achieve healthy lifespan, namely ‘‘healthspan’’, is get-
ting higher in all countries whose societies are heavily aging.
Therefore, it is critical and urgent to have better understanding
of the structure and the dynamics of the regulatory system for
aging and longevity in mammals. Once we start understanding
these aspects, then we might be able to design more effective
anti-aging interventions that can optimize the balance between
robustness and frailty throughout our body. Based on the concept
of the NAD World, administering NMN at an appropriate timing or
age might help achieve this healthy balance by enhancing and
coordinating NAD biosynthesis and SIRT1 activity. Although more
extensive research is necessary to further clarify this concept, dis-
secting the system control of the NAD World will provide the ﬁrst
step towards the brighter future of our aging world.
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